Savara (NASDAQ:SVRA) released its earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.14, Fidelity Earnings reports.
NASDAQ SVRA traded down $0.07 during trading on Friday, reaching $0.84. 581,000 shares of the company’s stock were exchanged, compared to its average volume of 394,757. The stock has a market cap of $40.28 million, a P/E ratio of -0.65 and a beta of 0.10. The company has a debt-to-equity ratio of 0.22, a quick ratio of 12.61 and a current ratio of 12.61. The company has a 50 day moving average price of $1.34 and a two-hundred day moving average price of $4.38. Savara has a 1 year low of $0.82 and a 1 year high of $11.96.
A number of research firms recently issued reports on SVRA. ValuEngine upgraded Savara from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. LADENBURG THALM/SH SH reiterated a “hold” rating and issued a $1.00 target price on shares of Savara in a report on Thursday, October 3rd. Evercore ISI set a $17.00 target price on Savara and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Zacks Investment Research raised Savara from a “sell” rating to a “hold” rating in a report on Friday. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $9.09.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.